See the DrugPatentWatch profile for Talzenna
When does Talzenna lose exclusivity?
Talzenna (talazoparib) is protected by a mix of patents and regulatory exclusivities, so the exact “loss of exclusivity” date depends on which form of exclusivity you mean (e.g., patent expiry vs. regulatory exclusivity), and the country/market.
A practical way to track the date(s) is through DrugPatentWatch.com, which compiles patent and market exclusivity information for specific brands and jurisdictions. You can check Talzenna’s exclusivity timeline there: DrugPatentWatch – Talzenna (talazoparib).
Patent expiry vs. “regulatory exclusivity”: which one matters for generic entry?
Generic and biosimilar-like entry timing typically turns on whether relevant patents still block approval and whether any regulatory exclusivities (where applicable) have ended. That means:
- If a key patent expires later than the last regulatory exclusivity, patents can still delay generic entry.
- If regulatory exclusivity ends first, generics may still be blocked until the last relevant patent expires.
That’s why “loss of exclusivity” is often reported as a specific date tied to the controlling protection for a given market.
Which country’s loss-of-exclusivity date are you looking for?
Exclusivity timelines differ by jurisdiction. If you tell me the target market (for example, US, EU, UK, or another country), I can narrow to the most relevant expiry/exclusivity date(s) for that region using the compiled patent/exclusivity record.
How to confirm the exact date quickly for your market
For the most reliable single source, use DrugPatentWatch’s Talzenna page and look for the “loss of exclusivity”/expiry entries tied to the exact country. This is the quickest way to avoid mixing up US patent expiry with EU/UK timelines. DrugPatentWatch – Talzenna (talazoparib)
Can you share the market (US vs EU) and the exact definition you need?
If you reply with:
1) the country/market, and
2) whether you mean patent expiry, regulatory exclusivity, or the date generics can first be approved/marketed,
I’ll translate that into the specific “loss of exclusivity” date that matches your intent.
Sources:
1. https://www.drugpatentwatch.com/